Ivosenib 250 mg

How does ivosidenib work and what is IDH1 mutation in AML and cholangiocarcinoma?

IDH1 mutations represent one of the most elegant examples of metabolic oncology — a single point mutation in a normal metabolic enzyme that produces a completely new, toxic metabolic product that rewires cell biology in ways that drive cancer, and that can be reversed by a drug specifically designed to block the mutant enzyme’s abnormal activity.

What IDH1 normally does — its role in normal cell metabolism

Isocitrate dehydrogenase 1 (IDH1) is a metabolic enzyme found in the cytoplasm and peroxisomes of virtually all human cells. Its normal function is a single, well-defined step in the citric acid cycle: converting isocitrate to alpha-ketoglutarate (α-KG), with the concurrent reduction of NADP+ to NADPH. This is a housekeeping metabolic reaction — normal IDH1 performs it faithfully in every cell, generating α-KG as a useful metabolic intermediate and NADPH as an antioxidant cofactor.

In a cell with normal IDH1, this reaction simply keeps the citric acid cycle moving and contributes to cellular redox balance. Nothing unusual happens.

What the IDH1 mutation does — gaining a completely new, toxic enzymatic function

This is the central insight of IDH1 oncology: the most common IDH1 mutations (occurring at the R132 position — R132H, R132C, R132S, and others) don’t simply inactivate the enzyme. They confer a completely new catalytic activity — called a gain-of-function neomorphic mutation — that the normal enzyme doesn’t possess.

IDH1 mutation and overexpression in some cancers lead to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1 by blocking enzymatic activity and further differentiation of cancer cells. More specifically: the mutated IDH1 enzyme reduces 2-HG levels. In vitro and in vivo studies confirm lowered 2-HG levels and increased myeloid cells.

The mutant IDH1 enzyme, rather than converting isocitrate to α-KG, instead converts α-KG to a structurally similar but metabolically toxic compound called 2-hydroxyglutarate (2-HG). 2-HG is sometimes called an “oncometabolite” — a metabolic product that has no normal physiological role but actively drives cancer when produced in excess.

How 2-HG drives cancer — the epigenetic mechanism

2-HG’s oncogenic activity operates primarily through epigenetic disruption rather than direct DNA mutation or kinase signalling. α-KG is a required cofactor for a family of enzymes called α-KG-dependent dioxygenases, which include the TET family of DNA demethylases and the Jumonji family of histone demethylases. These enzymes maintain normal patterns of DNA and histone methylation — the chemical tags that control which genes are expressed and which are silenced.

2-HG is structurally similar enough to α-KG to competitively inhibit these dioxygenases, but cannot substitute for α-KG’s functional role. When mutant IDH1 floods the cell with 2-HG, it competitively blocks TET enzymes and Jumonji demethylases from performing their normal demethylation work. The result is a hypermethylated epigenetic state — excessive methylation across the DNA and histones — that silences genes responsible for normal cellular differentiation.

In plain terms: the cancer cell becomes stuck in an immature, undifferentiated state because the epigenetic machinery that would normally instruct it to mature and differentiate has been chemically jammed by 2-HG’s interference. This epigenetic blockade of differentiation is the fundamental mechanism by which IDH1 mutations drive leukemia and cholangiocarcinoma.

Why IDH1 mutations cause AML specifically

In normal haematopoiesis (blood cell production), haematopoietic stem cells and progenitor cells must receive appropriate signals to differentiate into mature blood cells — red cells, platelets, neutrophils, monocytes. This differentiation program is governed partly by the epigenetic machinery that 2-HG disrupts. When IDH1 mutations occur in haematopoietic progenitor cells, the epigenetic blockade locks these cells in an immature blast state, unable to complete their normal differentiation program. Instead of maturing and eventually being replaced by new progenitors in the normal cycle, these blasts accumulate — producing AML, a cancer defined by the accumulation of immature, non-functional blast cells in the bone marrow and blood.

IDH1 mutations occur in approximately 6-10% of AML cases, making them one of the more common targetable mutations in this disease.

Why IDH1 mutations cause cholangiocarcinoma

The same epigenetic disruption that drives AML when it occurs in haematopoietic cells drives biliary epithelial cell transformation when it occurs in cholangiocytes — the cells lining the bile ducts. Mutations in the metabolic enzyme IDH1 occur in up to approximately 20% of patients with intrahepatic cholangiocarcinoma. The hypermethylator phenotype produced by 2-HG accumulation disrupts normal biliary cell differentiation and promotes malignant transformation in cholangiocytes through the same α-KG-dependent dioxygenase inhibition mechanism, though the specific downstream gene silencing consequences differ in biliary cells compared to haematopoietic cells.

How ivosidenib restores normal cell biology

Ivosidenib is a selective inhibitor of mutant IDH1 enzymes, particularly targeting the R132 mutation. This action aids in restoring normal cellular differentiation and diminishing the production of 2-hydroxyglutarate (2-HG), a metabolite associated with the development of leukemia.

By occupying the active site of the mutant IDH1 enzyme and blocking its neomorphic catalytic activity, ivosidenib prevents the conversion of α-KG to 2-HG. With 2-HG production suppressed, the TET enzymes and Jumonji demethylases are relieved of competitive inhibition and can resume their normal DNA and histone demethylation work. This gradual restoration of normal epigenetic patterns allows the cancer cells to re-engage their differentiation programs — maturing into functional, terminally differentiated cells rather than remaining as immature, proliferating blasts.

This is fundamentally different from how most targeted therapies work in this conversation. Kinase inhibitors like alectinib or osimertinib block a signalling pathway to induce cell death. Ivosidenib restores a metabolic and epigenetic process to re-educate cancer cells into differentiating normally — a strategy called differentiation therapy, the same conceptual approach that underlies ATRA (all-trans retinoic acid) in APL and the enasidenib mechanism for IDH2-mutated AML we discussed earlier.

Why differentiation therapy explains the differentiation syndrome risk

This mechanistic understanding directly explains differentiation syndrome. When ivosidenib successfully restores differentiation in IDH1-mutated AML blast cells, those blasts can undergo rapid, simultaneous differentiation into mature myeloid cells. Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells and may be life-threatening or fatal if not treated. The sudden release of large numbers of differentiating myeloid cells produces systemic inflammation — cytokine release, capillary leak, tissue infiltration — that manifests as the fever, respiratory distress, effusions, and oedema characteristic of the syndrome.

This is the drug working as intended — forcing leukaemic blasts to differentiate — but doing so at a pace that overwhelms the body’s capacity to clear the differentiating cells and manage the inflammatory response they generate. Understanding this mechanism is precisely why the treatment for differentiation syndrome is corticosteroids to manage the inflammatory response, not stopping ivosidenib — the drug causing the problem is doing exactly what it should.

Why ivosidenib spares normal cells

Normal cells carry wild-type IDH1 — the R132 mutation is a somatic, tumour-specific event not present in normal tissue. Ivosidenib’s selectivity for the mutant enzyme means it has minimal activity against normal IDH1, which is why the drug doesn’t disrupt normal citric acid cycle function in healthy cells and produces the relatively manageable side-effect profile seen in cholangiocarcinoma patients who don’t carry the AML-specific differentiation syndrome risk.

The bigger picture

Ivosidenib works by blocking a gain-of-function metabolic enzyme that produces a toxic oncometabolite — 2-HG — that drives cancer by competitively inhibiting the epigenetic machinery governing cell differentiation. Removing 2-HG by blocking the mutant IDH1 enzyme restores the epigenetic landscape and allows cancer cells to re-engage their normal differentiation programs, converting leukaemic blasts back toward mature blood cells rather than directly killing them. This differentiation therapy approach is mechanistically elegant, clinically effective as shown by AGILE’s threefold OS improvement, and inherently linked to the most important safety consideration — differentiation syndrome — through the very mechanism that makes the drug work.